Immatics: A Promising TCR Pipeline
Immatics, a biotech company working on promising cell-based immunotherapies for solid cancers, has a promising TCR-engineered ...
Cantargia’s Strong Phase 2 Clinical Data in Pancreatic Cancer with Nadunolimab Published in Clinical Cancer Research
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced the publication of the results using nadunolimab (CAN04) ...
Theriva Biologics Announces Pricing of $2.5 Million Public Offering
ROCKVILLE, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) -- (NYSE American: TOVX) (“Theriva” or the “Company”), a diversified ...
ALZFORUM1d
Reconceptualizing the BBB: Is It Time to Swap ‘Barrier’ for ‘Border'?
A group of scientists argue, in a review published in Fluids and Barriers of the CNS earlier this year, that it’s time to adopt a more apt metaphor. Jan Pieter Konsman and Jerome Badaut of the ...
Pharmabiz18d
Theriva achieves target patient enrollment in VIRAGE phase 2b trial of VCN-01 with gemcitabine/nab-paclitaxel to treat metastatic pancreatic cancer
Rockville, Maryland Wednesday, September 25, 2024, 18:00 Hrs [IST] ...
eLife6d
A single microRNA miR-195 rescues the arrested B cell development induced by EBF1 deficiency
This useful study reports that the exogenous expression of the microRNA miR-195 can partially compensate in early B cell development for the loss of EBF1, one of the key transcription factors in B ...